Endocrine Abstracts

Background: 2016 marks the 20th anniversary of PRRT and may mark the year that a commercially available PRRT product is approved in the United States for the treatment of Neuroendocrine Tumors (NETs). During these 20+ years PRRT was available to many in either small institutional studies or via single center compassionate care programs. Many retrospective analysis were done on this data showing the extended progression free survival (PFS) compared to drugs approved for the tre...

Background: Somatostatin receptor ligands (SRLs) are first-line standard-of-care therapies for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), showing efficacy in tumour and symptom control with an established safety profile. However, disease progression may occur despite standard-dose SRL treatment, requiring more aggressive and toxic treatments. Retrospective/non-randomized data suggest higher-dose SRLs may benefit patients with GEP-NETs who do not respond to stand...

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which frequently develop metastatic disease, represent an estimated 70% of NETs. There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and ...

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent an estimated 70% of NETs. GEP-NETs frequently develop metastatic disease with limited treatment options. For well-differentiated high grade 2 and 3 GEP-NETs, current therapies include peptide receptor radionuclide therapy (PRRT), somatostatin analogues, chemotherapy, cytoreduction, and molecular targeted therapies (everolimus, sunitinib). PRRT uses radiolabeled somatostatin analogues to selectively t...

Background: Targeted radionuclide therapies (TRTs) have changed the treatment paradigm of neuroendocrine tumors (NET) and are expected to be widely available for patients with various gastroenteropancreatic (GEP)-NET phenotypes. However, while they have great potential, TRT-based therapeutic strategies for high-grade GEP-NET demonstrate variable outcomes, and there is a current lack of tools to identify patients who are likely to respond to TRT. To address this need, the rando...

Background: Finding relevant neuroendocrine tumor (NET) trials remains a challenge for patients and healthcare professionals (HCPs). Clinicaltrials.gov’s taxonomy associates many conditions with NETs, complicating the discovery process. As of 6/30/23 clinicaltrials.gov listed 700 recruiting, phase 1-3 interventional trials using the terms Neuroendocrine Tumors, Pheochromocytoma, and Paraganglioma. Many of these trials are not relevant for patients with NETs. Even with sev...

Acknowledgements: This study was funded by Camurus AB. Medical writing support was provided by Costello Medical and funded by Camurus AB.Background: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. However, disease progression usually occurs despite standard-dose SRL treatment, requiring m...